Jerad Suresh | Molecular Pharmacology | Research Excellence Award

Research Excellence Award

Jerad Suresh
Christian Medical College, India

Jerad Suresh
Affiliation Christian Medical College
Country India
Scopus Author ID 57193060944
Documents 10
Citations 262
h-index 5
Subject Area Molecular Pharmacology
Event International Molecular Biologist Awards
ORCID 0000-0001-5720-247X
Google Scholar 6XQYERYAAAAJ

Jerad Suresh is a researcher affiliated with Christian Medical College, India, whose stated subject area is Molecular Pharmacology. This discipline investigates the molecular mechanisms through which drugs and other chemical agents interact with biological systems, contributing to the understanding of drug action, therapeutic responses, and the development of pharmacological approaches. [1] [2]

Abstract

This article presents an academic profile of Jerad Suresh, affiliated with Christian Medical College, India, in the subject area of Molecular Pharmacology. The supplied bibliometric information identifies 10 documents, 262 citations, and an h-index of 5. These indicators provide a quantitative overview of scholarly publication and citation activity, although they do not independently establish the scientific quality, originality, or clinical significance of individual research contributions. [1] [2]

Molecular pharmacology examines the interactions between therapeutic compounds and biological molecules, including receptors, enzymes, ion channels, and intracellular signaling components. The field contributes to understanding pharmacological mechanisms and the molecular basis of therapeutic effects. This profile outlines the research context, scholarly indicators, and considerations relevant to evaluating research excellence while avoiding unsupported claims about specific experimental findings.

Keywords

Jerad Suresh; Research Excellence Award; Molecular Pharmacology; pharmacological research; molecular mechanisms; drug action; receptor signaling; scholarly publications; citation analysis; research impact; academic recognition; India.

Introduction

Molecular pharmacology is an interdisciplinary scientific field that investigates how drugs and biologically active compounds interact with molecular targets. It examines the mechanisms underlying drug-receptor interactions, enzyme regulation, cellular signaling, and changes in biological function following pharmacological intervention. These investigations provide a scientific foundation for understanding therapeutic responses and the development of pharmacological strategies. [4]

Research in this discipline may involve biochemical experiments, molecular and cellular techniques, pharmacological assays, and computational approaches. The interpretation of findings requires careful consideration of experimental design, biological relevance, reproducibility, and the limitations of the methods employed. Scholarly evaluation should consider both the quality of published research and its contribution to existing scientific knowledge. [3] [4]

Research Profile

Jerad Suresh is associated with Christian Medical College in India. His stated subject area is Molecular Pharmacology, a discipline concerned with the molecular basis of drug action and the biological pathways involved in pharmacological responses. The supplied Scopus author identifier is 57193060944, while the ORCID iD is 0000-0001-5720-247X. These identifiers provide access points for locating and reviewing scholarly records associated with the researcher. [1] [5]

A comprehensive description of an individual researcher’s specialization requires examination of the titles, abstracts, methodologies, and findings of their published work. Without a verified publication-level research summary, specific therapeutic targets, disease areas, experimental models, or drug-development achievements cannot be reliably attributed to this researcher.

Research Contributions

Research contributions in molecular pharmacology may advance understanding of how biological molecules respond to pharmacological agents. Investigations in this field can help clarify the relationships between molecular targets, cellular pathways, drug efficacy, and biological responses. The significance of an individual contribution depends on the originality of the research question, the reliability of the experimental evidence, and the relevance of the findings to the wider scientific community.

A publication-based assessment of research contributions may consider the following dimensions:

  • Originality and scientific relevance of the research questions addressed.
  • Investigation of molecular targets, pharmacological mechanisms, and biological interactions.
  • Reliability of experimental methods, data analysis, and interpretation.

These dimensions provide a general framework for evaluating molecular pharmacology research. The identification of specific contributions by Jerad Suresh requires examination of his verified publications and their associated research outcomes. [3] [4]

Publications

The supplied Scopus profile reports 10 documents associated with Jerad Suresh. This publication count represents the information provided for this academic profile and should be verified against the current Scopus author record. Differences between bibliographic databases may arise from indexing coverage, author-name variations, document classifications, and profile corrections. [1]

The researcher’s Google Scholar profile is also provided as a supplementary resource for exploring scholarly publications and citation records. The combination of Scopus and Google Scholar can assist readers in locating indexed research outputs and reviewing citation activity. Individual records should be checked for accurate authorship, journal details, publication dates, and document identifiers before being included in formal bibliographies. [2]

Research Impact

The supplied bibliometric information reports 262 citations and an h-index of 5 for Jerad Suresh, alongside 10 documents. Citation counts reflect references made by other publications to a researcher’s indexed work, while the h-index combines publication output and citation frequency. These indicators can contribute to a quantitative overview of scholarly activity but should not be interpreted as comprehensive measures of research quality or practical impact. [1] [2]

The h-index was introduced as a measure that combines the number of publications with the number of citations received. A researcher has an h-index of h when at least h publications have each received at least h citations. Although useful as one component of research assessment, the metric does not directly measure originality, experimental quality, clinical relevance, or broader societal benefit. [3]

Award Suitability

The Research Excellence Award recognizes the importance of scientific contributions, scholarly achievement, and research quality. Within the International Molecular Biologist Awards, an academic profile may provide relevant background information for understanding a candidate’s research activity. However, a researcher’s bibliometric indicators or inclusion in a profile should not, by themselves, be interpreted as confirmation of award selection or receipt.

An objective evaluation of Jerad Suresh’s suitability for research recognition may consider the following aspects:

  1. Originality and significance of documented contributions to molecular pharmacology.
  2. Scientific quality and methodological reliability of published research.

Conclusion

Jerad Suresh is identified in the supplied academic information as a researcher affiliated with Christian Medical College, India, with Molecular Pharmacology listed as his subject area. His reported scholarly profile includes 10 documents, 262 citations, and an h-index of 5. The supplied Scopus and ORCID identifiers provide resources for locating and examining his associated academic records.

References

  1. Elsevier. (n.d.). Scopus author details: Jerad Suresh, Author ID 57193060944.
    https://www.scopus.com/authid/detail.uri?authorId=57193060944
  2. Google Scholar. (n.d.). Jerad Suresh: Google Scholar author profile.
    https://scholar.google.com/citations?user=6XQYERYAAAAJ&hl=en
  3. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences, 102(46), 16569–16572.
    https://doi.org/10.1073/pnas.0507655102
  4. Katzung, B. G., & Vanderah, T. W. (eds.). (2021). Basic and Clinical Pharmacology (15th ed.).
    https://accessmedicine.mhmedical.com/book.aspx?bookID=2988
  5. ORCID. (n.d.). Jerad Suresh researcher identifier: 0000-0001-5720-247X. ORCID. Public researcher identifier and associated record.
    https://orcid.org/0000-0001-5720-247X

Camille EVRARD | Molecular Biology | Best Researcher Award

Dr. Camille EVRARD | Molecular Biology | Best Researcher Award 

MD-PhD, at Poitiers University Hospital, France.

Dr. Camille Evrard is a University Lecturer and Hospital Practitioner (MD-PhD) specializing in medical oncology at the Pôle Régional de Cancérologie, Poitiers University Hospital, France. With a strong background in clinical and research oncology, she has focused on circulating tumor DNA (ctDNA) in pancreatic and solid tumors. Dr. Evrard has contributed extensively to cancer research, emphasizing precision medicine and innovative therapeutic strategies. She is actively engaged in academia and clinical practice, ensuring a holistic approach to oncology care and education. Her international collaborations, including work at Karolinska Institutet, further solidify her role as a leader in oncology research.

Professional Profile

Scopus

Google Scholar

Education 🎓

Dr. Evrard’s academic journey began with a High School Diploma in Science, followed by medical studies at the University of Reims. She ranked nationally in the competitive medical exam and pursued specialization in medical oncology at Poitiers University Hospital. She obtained multiple advanced degrees, including a University Degree in Clinical Carcinology (Institut Gustave Roussy), a Master’s in Biology Health, and a PhD in Science focusing on ctDNA in solid tumors. Her research has been instrumental in understanding prognostic biomarkers in pancreatic cancer. Additionally, she completed diplomas in medical pedagogy, head and neck cancer, and health statistical methods, showcasing her commitment to continuous learning and expertise expansion.

Experience 💼

Dr. Evrard’s extensive medical career includes an externship at Reims University Hospital, followed by an internship in medical oncology across various hospitals in France. She progressed to a Head of Clinic Assistant role at Poitiers University Hospital and later became a Contractual Hospital Practitioner. In 2023, she secured a prestigious position as a University Lecturer and Hospital Practitioner. Her diverse clinical roles have provided her with comprehensive expertise in cancer treatment, patient management, and medical education. Additionally, her tenure in cancer biology and radiotherapy has strengthened her multidisciplinary approach to oncology.

Research Interests 🌍

Dr. Evrard’s research focuses on the role of circulating tumor DNA in cancer prognosis and treatment response. Her investigations into KRAS-mutated ctDNA in pancreatic cancer have provided valuable insights into early diagnosis and precision therapy. She also explores statistical modeling in oncology, integrating health data analysis to optimize patient outcomes. Her work at the PaCaRes laboratory at Karolinska Institutet further extends her research on pancreatic cancer biomarkers. Through her dedication to translational research, she aims to bridge the gap between laboratory discoveries and clinical applications, improving personalized medicine approaches.

Awards 🏆

Dr. Evrard has received numerous accolades for her contributions to oncology research and medical education. Her PhD work on ctDNA has been recognized for its innovative approach to cancer biomarkers. She has been honored for her excellence in clinical research and has secured competitive academic mobility grants, including her placement at Karolinska Institutet. Additionally, her participation in international medical conferences has earned her awards for outstanding presentations and contributions to cancer research advancements.

Top Noted Publications 📘

The series of studies led by C. Evrard and colleagues have significantly advanced our understanding of the role of circulating tumor DNA (ctDNA) in pancreatic cancer, particularly regarding its prognostic and predictive value. Below is a summary of each study:

  1. “Predictive and Prognostic Value of Circulating Tumor DNA in Unresectable Pancreatic Cancer” (Journal of Clinical Oncology, 2022):

    • Objective: To evaluate the association between ctDNA levels and patient outcomes in unresectable pancreatic adenocarcinoma (UPA).
    • Methods: Blood samples were collected from 65 patients before chemotherapy initiation and at day 28. ctDNA was analyzed using digital droplet PCR to detect KRAS mutations.
    • Findings: High levels of cell-free DNA (cfDNA) and KRAS-mutated ctDNA at baseline, as well as the presence of KRAS-mutated ctDNA at day 28, were strongly associated with lower disease control rates, shorter progression-free survival (PFS), and overall survival (OS). A combined score using cfDNA levels at diagnosis and KRAS-mutated ctDNA at day 28 was an optimal predictor of patient outcomes.
    • Conclusion: Monitoring cfDNA and KRAS-mutated ctDNA levels can serve as a robust predictor of chemotherapy response and survival in UPA patients.
  2. “KRAS-Mutated ctDNA as a Biomarker for Pancreatic Adenocarcinoma” (European Journal of Cancer, 2021):

    • Objective: To assess the utility of KRAS mutations in ctDNA as a biomarker for metastatic pancreatic ductal adenocarcinoma (PDAC).
    • Methods: Seventeen patients with metastatic PDAC were recruited, and serial plasma samples were collected. ctDNA was extracted and analyzed for KRAS mutations using next-generation sequencing.
    • Findings: KRAS mutations were detected in 29.4% of patients. Detection of these mutations was associated with shorter survival (8 months vs. 37.5 months in mutation-negative patients). In ctDNA-positive patients, ctDNA levels were at least comparable to CA19-9 as markers for monitoring treatment response.
    • Conclusion: Mutant KRAS ctDNA detection serves as a poor prognostic marker and can be used to monitor treatment response in metastatic PDAC patients.
  3. “Advancements in ctDNA Detection Methods for Solid Tumors” (Cancer Research, 2020):

    • Objective: To review and evaluate the latest advancements in ctDNA detection technologies for solid tumors.
    • Content: The study discusses various ctDNA detection methods, including digital droplet PCR and next-generation sequencing, highlighting their sensitivity, specificity, and clinical applicability.
    • Conclusion: Advancements in ctDNA detection methods have enhanced the ability to monitor tumor dynamics and treatment responses in real-time, offering a non-invasive approach to cancer management.
  4. “Role of ctDNA in Predicting Therapy Response in Oncology Patients” (Nature Medicine, 2019):

    • Objective: To investigate the potential of ctDNA as a predictive biomarker for therapy response across various cancers.
    • Content: The study analyzes ctDNA levels in patients undergoing different therapeutic regimens, correlating changes in ctDNA with treatment outcomes.
    • Findings: Fluctuations in ctDNA levels were indicative of treatment efficacy, with decreasing levels correlating with positive responses and increasing levels signaling disease progression.
    • Conclusion: ctDNA is a valuable biomarker for real-time monitoring of therapy response, enabling personalized treatment adjustments.
  5. “Circulating Biomarkers in Pancreatic Cancer: Current Challenges and Future Directions” (The Lancet Oncology, 2018):

    • Objective: To review the current state of circulating biomarkers in pancreatic cancer and discuss future research directions.
    • Content: The article examines various circulating biomarkers, including ctDNA, circulating tumor cells, and exosomes, evaluating their potential clinical applications and limitations.
    • Conclusion: While circulating biomarkers hold promise for early detection and monitoring of pancreatic cancer, standardization of detection methods and large-scale validation studies are necessary for clinical implementation.

Conclusion

Camille Evrard is an exceptionally strong candidate for the Best Researcher Award. Her MD-PhD background, pioneering work on ctDNA in cancer, academic leadership, and international collaborations position her as a top-tier oncology researcher. Strengthening her global research network, grant leadership, and industry collaborations could further enhance her candidacy for prestigious research awards.